Pfizer suspends worldwide studies for tanezumab in osteoarthritis
This article was originally published in Scrip
Executive Summary
Pfizer has suspended worldwide clinical trials of its investigational pain drug, tanezumab, for osteoarthritis at the request of the US FDA after some patients receiving the drug experienced a worsening of their osteoarthritis that led to joint replacement. Trials for this population had reached the Phase III stage.
You may also be interested in...
Regeneron Partners NGF Antibody With Teva To Mitigate Risks
Regeneron and Teva will partner on the development and commercialization of the late-stage nerve growth factor antibody fasinumab for pain in a deal that will help Regeneron fund a 10,000-patient safety database.
Regeneron Revives NGF Inhibitor With Phase II/III Data; Safety Issue Remains
Regeneron Pharmaceuticals Inc. reported statistically significant pain relief for osteoarthritis sufferers enrolled in the company's Phase II/III clinical trial for fasinumab, but the data didn't relieve concerns about neuro-musculoskeletal side effects for medicines that inhibit nerve growth factor (NGF).
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.